- Home
- TBI vs ITOS Comparison
TBI vs ITOS Comparison
Compare TBI & ITOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TBI
- ITOS
- Stock Information
- Founded
- TBI 1985
- ITOS 2011
- Country
- TBI United States
- ITOS United States
- Employees
- TBI N/A
- ITOS N/A
- Industry
- TBI Professional Services
- ITOS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TBI Consumer Discretionary
- ITOS Health Care
- Exchange
- TBI Nasdaq
- ITOS Nasdaq
- Market Cap
- TBI 248.3M
- ITOS 270.7M
- IPO Year
- TBI 1996
- ITOS 2020
- Fundamental
- Price
- TBI $6.34
- ITOS $7.41
- Analyst Decision
- TBI Buy
- ITOS Strong Buy
- Analyst Count
- TBI 2
- ITOS 3
- Target Price
- TBI $11.50
- ITOS $21.33
- AVG Volume (30 Days)
- TBI 152.5K
- ITOS 205.1K
- Earning Date
- TBI 02-19-2025
- ITOS 03-05-2025
- Dividend Yield
- TBI N/A
- ITOS N/A
- EPS Growth
- TBI N/A
- ITOS N/A
- EPS
- TBI N/A
- ITOS N/A
- Revenue
- TBI $1,567,393,000.00
- ITOS $35,000,000.00
- Revenue This Year
- TBI N/A
- ITOS $271.18
- Revenue Next Year
- TBI N/A
- ITOS N/A
- P/E Ratio
- TBI N/A
- ITOS N/A
- Revenue Growth
- TBI N/A
- ITOS N/A
- 52 Week Low
- TBI $6.06
- ITOS $7.06
- 52 Week High
- TBI $12.66
- ITOS $18.75
- Technical
- Relative Strength Index (RSI)
- TBI 31.22
- ITOS 45.45
- Support Level
- TBI $7.14
- ITOS $7.06
- Resistance Level
- TBI $7.86
- ITOS $7.61
- Average True Range (ATR)
- TBI 0.44
- ITOS 0.25
- MACD
- TBI -0.14
- ITOS 0.01
- Stochastic Oscillator
- TBI 11.60
- ITOS 40.23
About TBI TrueBlue Inc.
TrueBlue Inc is a provider of staffing and workforce management solutions. Its reportable segments include PeopleReady offers industrial staffing services. PeopleManagement offers contingent and productivity-based on-site industrial staffing services and PeopleScout offers recruitment process outsourcing, talent advisory services, and managed service provider services. It generates maximum revenue from the PeopleReady segment.
About ITOS iTeos Therapeutics Inc.
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.